Apollomics (APLM)
Develops vebreltinib and other oncology candidates through global trials and territorial partnerships.
Something off on this page? Send us feedback.
Develops oncology drug candidates, led by the c-MET inhibitor vebreltinib, and earns demonstrated revenue through territorial licensing. Its international clinical program and partner-led China approvals rely on external research, manufacturing, and regional-development relationships.
Develops oncology candidates aimed at tumor-driving molecular pathways and immune mechanisms, with vebreltinib, an oral selective CNS-penetrant c-MET inhibitor, as the lead asset. The current program prioritizes MET-amplified non-small cell lung cancer while evaluating other MET-altered solid tumors through the multi-country SPARTA study.
The remaining portfolio pairs APL-102, a multiple tyrosine kinase inhibitor, with immuno-oncology candidates APL-501, an anti-PD-1 antibody; APL-502, an anti-PD-L1 antibody; and APL-801, an anti-PD-L1/anti-CD40 bispecific antibody. Partner-led development has produced China approvals for vebreltinib and APL-502, while Apollomics retains defined ex-China rights.
Revenue has come from territorial licensing rather than sales of a marketed drug. Clinical operations span North America, Europe, and Asia-Pacific, supported by a streamlined team across Foster City, Taipei, and Hangzhou; the business uses CROs, manufacturers, and regional partners rather than an owned commercial infrastructure.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $3.3M · Total debt $643.0K · Total assets $6.7M · Shareholders' equity −$3.2M
- Revenue
- $0
- Operating income
- $1.1M
- Net income
- $1.6M
No dividends on record.
| Institutions4 holders · as of Mar 31, 2026 | 0.03% | 590 shares | |
| Insiders8 holders · as of Aug 24, 2026 | 74.81% | 1.64M shares | |
| Otherremainder | 25.16% | 552.6K shares |
2.20M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Hung-Wen ChenInsiderdirector, officer: Chief Executive Officer | 65.94% | 1.45M | Form 4filed Aug 17, 2026 ↗ |
Yi-Kuei Chen1Insiderdirector, officer: Chief Operating Officer | 6.20% | 136,248 | Form 4filed Aug 17, 2026 ↗ |
Peter Kuan-How LinInsiderofficer: Chief Financial Officer | 2.23% | 48,979 | Form 4filed Aug 17, 2026 ↗ |
Hong-Jung ChenInsiderdirector | 0.16% | 3,620 | Form 4filed Jun 16, 2026 ↗ |
Yi-An ChuInsiderdirector | 0.07% | 1,500 | Form 4filed Jun 16, 2026 ↗ |
| See all 16 → | |||
- Reported at 4.97% on Aug 14, 2026, under the 5% line, so no further filing is required.
Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Yi-Kuei Chen | director, officer: Chief Operating Officer | +20,000 | $15.00 |
| Aug 14, 2026 | Peter Kuan-How Lin | officer: Chief Financial Officer | +26,667 | $15.00 |
| Aug 14, 2026 | Hung-Wen Chen | director, officer: Chief Executive Officer | +536,667 | $14.07 |
- Novartis (ADR)
Approved MET therapy in the same METex14 NSCLC setting.
- AstraZeneca (ADR)
Approved savolitinib contests MET-altered NSCLC in China.
- Merck
Keytruda is a leading approved PD-1 therapy in lung cancer.
- HUTCHMED (ADR)
China MET drug-development rival through savolitinib.
- Bristol-Myers Squibb
Opdivo is an established PD-1 treatment across NSCLC settings.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Apollomics | $27.35 | +1.52% | $60.1M | — | — | 7.1 | — |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Merck | $151.14 | −0.33% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| HUTCHMED (ADR) | $13.22 | +9.80% | $2.10B | 116.9 | — | 3.9 | +100.4% |
| Bristol-Myers Squibb | $67.38 | −0.40% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Median | 24.5 | 16.3 | 4.1 | +5.7% |